Cáncer de Hígado

Compartir:
Más

Bibliografía

  1. Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist. 2005 Apr;10(4):269-81.
  2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004 Nov;127(5 Suppl 1):S218-24.
  3. Marin-Hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol. 2003 Jul;47(1):13-27.
  4. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun;239(6):818-25
  5. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol. 2003 Feb;9(2):193-200.
  6. Ruan DT, Warren RS. Liver-directed therapies in colorectal cancer. Semin Oncol. 2005 Feb;32(1):85-94.
  7. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol. 2005 Jun;31(5):533-9. Epub 2005 Apr 26.
  8. Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, Carey LC, Rosemurgy AS. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg. 2005 Nov;190(5):810-5.
  9. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005 Mar 1;23(7):1358-64.
  10. Ruers TJ, de Jong KP, Ijzermans JN. Radiofrequency for the treatment of liver tumours. Dig Surg. 2005;22(4):245-53.
  11. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005 May;41(5):1130-7.
  12. Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, Sterling R, Shiffman M, Posner M. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant. 2004 Oct;18(5):502-12
  13. Kerkar S, Carlin AM, Sohn RL, Steffes C, Tyburski J, Littrup P, Weaver D. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery. 2004 Oct;136(4):770-9.
  14. Seifert JK, Springer A, Baier P, Junginger T. Liver resection or cryotherapy for colorectal liver metastases: a prospective case control study. Int J Colorectal Dis. 2005 Nov;20(6):507-20.
  15. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, Shoda J, Hata M, Abei M, Igaki H, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005 May 15;11(10):3799-80
  16. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005 Dec 1;23(34):8739-47.
  17. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):329-36
  18. Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, Wong A, Delclos M, Charnsangavej C, Janjan NA. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74.
  19. Wada H, Takai Y, Nemoto K, Yamada S. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1114-20
  20. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005 Oct;15(4):279-83.
  21. Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001 Dec;177(12):645-55
  22. Kavanagh BD, Schefter TE, Cardenes HR, Timmerman RD, Feigenberg S, Stieber V, Nedzi LA, Gaspar L. Biologically potent doses safely achieved in a multi-center trial of stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys 2004 Sep;61(1) (Supplement):S412
  23. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1371-8
  24. Kelsey CR, Schefter T, Nash SR, Russ P, Baron AE, Zeng C, Gaspar LE. Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy. Am J Clin Oncol. 2005 Dec;28(6):576-80.
  25. Becker G, Momm F, Schwacha H, Hodapp N, Usadel H, Geissler M, Barke A, Schmitt-Graff A, Henne K, Blum HE. Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: a case report. World J Gastroenterol. 2005 Aug 21;11(31):4923-6.

Escrito por Donald B. Fuller, M.D. – Radioncólogo

Estados Unidos

SAN DIEGO: (858) 505-4100
GRATUITO: (800) 790-3526

México

GRATUITO: 01-800-681-1839

2010 © Todos los derechos reservados | www.sdcyberknife.com